Delfi Diagnostics
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Delfi Diagnostics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,751 sponsors by registered trial count).
Delfi Diagnostics: 3 sponsored US clinical trials, none currently recruiting.
Delfi Diagnostics sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. The most-studied condition in this pipeline is Lung Cancer, with 1 trials.
Upper-quartile sponsor footprint
Delfi Diagnostics sits in the upper quartile of the sponsor corpus (#3,661 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung
NCT05306288
Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
NCT06145750
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT04825834
Therapeutic Areas
How the Delfi Diagnostics archive is shaped
3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Lung Cancer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.